Adma Biologics, Inc.
A maker of plasma-derived medicines for people with weakened immune systems, ADMA Biologics produces immune globulin therapies such as BIVIGAM and Nabi-HB, used to treat primary immunodeficiency and to guard against hepatitis B. The company was formed in 2013 when ADMA Biologics merged with Nabi Biologics, combining their plasma collection and manufacturing operations. Headquartered in Boca Raton, Florida, it collects plasma and turns it into treatments for immune deficiency patients.
Sold 14.41M
Bought 9.06M · Sold 3.32M
Bought 5.81M · Sold 8.59M
Granted 2.96M · Bought 14.0K · Sold 1.93M
Granted 7.33M · Bought 1.35M · Sold 1.79M
Bought 411.8K
Granted 83.9K · Sold 1.43M
Bought 308.8K
Granted 885.4K
Granted 2.09M · Bought 73.1K · Sold 389.8K
Granted 690.9K · Bought 530.6K · Sold 146.9K
Granted 403.5K · Sold 34.2K
Granted 153.5K · Bought 71.0K · Sold 38.0K
Granted 98.0K · Bought 125.0K · Sold 60.0K
Granted 134.6K · Sold 15.0K
Granted 104.4K · Bought 33.1K
Granted 52.4K · Bought 4.2K
Granted 45.6K
Granted 10.3K · Bought 33.7K
Granted 21.6K
Granted 2.52M
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Biotest Divestiture Trust10% owner · 2 transactions | — | 14.41Mas of Jun 2019 | — | — | 14.41M |
| Edelman Joseph +2 co-filers10% owner · 12 transactions | — | 13.26Mas of Sep 2021 | — | 9.06M | 3.32M |
| Biotest AG +1 co-filer10% owner · 2 transactions | — | 10.11Mas of May 2018 | — | 5.81M | 8.59M |
| Elms SteveDirector · 28 transactions | — | 6.21M | 2.96M | 14.0K | 1.93M |
| Grossman Adam SPresident and CEO, Director · 154 transactions | — | 3.84M | 7.33M | 1.35M | 1.79M |
| Aisling Capital Partners LLC +5 co-filers10% owner · 1 transaction | — | 3.62Mas of Oct 2013 | — | 411.8K | — |
| Fong BryantDirector · 5 transactions | — | 1.52Mas of Feb 2024 | 83.9K | — | 1.43M |
| Burrill & Co (BCF IV GP), LLC +1 co-filer10% owner · 1 transaction | — | 1.43Mas of Oct 2013 | — | 308.8K | — |
| Burrill Steven +2 co-filersDirector, 10% owner · 1 transaction | — | 885.4Kas of Feb 2012 | 885.4K | — | — |
| Lenz BrianEVP, CFO · 49 transactions | — | 703.0Kas of Mar 2024 | 2.09M | 73.1K | 389.8K |
| Grossman Jerrold BDirector · 42 transactions | — | 613.0K | 690.9K | 530.6K | 146.9K |
| Kestenberg-Messina Kaitlin M.COO and SVP, Compliance · 33 transactions | — | 446.2K | 403.5K | — | 34.2K |
| Guiheen Lawrence P.Director · 21 transactions | — | 373.0K | 153.5K | 71.0K | 38.0K |
| Kwon YoungDirector · 8 transactions | — | 263.0K | 98.0K | 125.0K | 60.0K |
| Tade Brad L.CFO and Treasurer · 7 transactions | — | 232.9K | 134.6K | — | 15.0K |
| Mond JamesEVP, CSO and CMO · 11 transactions | — | 137.5Kas of Feb 2021 | 104.4K | 33.1K | — |
| Demski Martha JDirector · 4 transactions | — | 56.6Kas of Mar 2023 | 52.4K | 4.2K | — |
| Finger Alison CecilyDirector · 3 transactions | — | 45.6K | 45.6K | — | — |
| Richman Eric IDirector · 6 transactions | — | 44.0Kas of Feb 2020 | 10.3K | 33.7K | — |
| R & R Investments VI LLC10% owner · 1 transaction | — | 39.3Kas of Feb 2012 | — | — | — |
| Salas Eduardo ReneDirector · 2 transactions | — | 21.6K | 21.6K | — | — |
| Kling Arnold PPresident, Director, 10% owner · 1 transaction | — | 8.5Kas of Feb 2012 | — | — | — |
| Goldstein Dov A MDDirector · 2 transactions | — | 7.5Kas of Feb 2020 | 2.52M | — | — |
| Warshaw Kirk MCFO, Secretary · 1 transaction | — | 5.2Kas of Feb 2012 | — | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -14.32M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.